BOSTON, May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics. These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic me ...

Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON, May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Gin ...

Ginkgo Bioworks (NYSE:DNA) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed, over the past few days, the number of DNA short shares available has recently sunk from around 750,000 to 0, according to financial data website Fintel. Now, this doesn’t mean that there aren’t any more shore shares available, as Fintel doesn’t sample every single brokerage. But it does show a clear surge in the ...

BOSTON, April 29, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of Myrtle Potter and Ross Fubini for election as independent directors at Ginkgo's upcoming annual meeting, scheduled to be held on June 13, 2024. Marijn Dekkers, who has served on Ginkgo's Board since 2019 and as Ginkgo's Board Chair from 2019 through 2023, and Reshma Kewalramani, who joined Ginkgo's Board in 2021 and serves as Nomi ...

IGDI与Ginkgo Bioworks合作 - IGDI与Ginkgo Bioworks宣布新合作，利用Ginkgo的ALE技术改进酸面团发酵剂产品[1] - IGDI计划利用Ginkgo的ALE技术，将新菌株演化至更高的生长速率，以进一步提升烘焙产品的口味和香气[3] IGDI的新产品Pater - IGDI开发了Pater产品，可改善面包的口味和香气，同时保持酸面团的活性和稳定性[2]

收购详情 - Ginkgo Bioworks宣布收购AgBiome的平台资产，包括超过115,000株完全测序和分离的菌株，超过5亿个独特基因序列，相关功能数据和元数据，以及AgBiome的开发管线[1] - 收购将扩展Ginkgo的专有统一宏基因组数据库，创造了一个深度和先进的农业生物发现和开发平台，为生物研发提供丰富资源[2] AgBiome成就 - AgBiome自2012年成立以来，通过其Genesis Discovery Platform，成功商业化了多种生物产品，包括Howler和Theia产品系列，同时开发了包括一打经过温室或田间验证的产品候选品在内的强大产品概念管线[3]

BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.  Novo Nordisk Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the partners aim to improve the manufacturing of Novo ...

Moderna公司 - Moderna公司在疫情期间因冠状病毒疫苗而获得数十亿美元的收入，但随着疫苗需求下降，股价也下跌[3] - Moderna公司可能在今年推出第二款产品，且计划在未来五年推出多达15款产品[4] Intellia Therapeutics - Intellia Therapeutics专注于CRISPR基因编辑技术，虽然尚未有产品上市，但在关键领域取得进展[7] - Intellia最近在其NTLA-2001用于心肌病的III期试验中给第一名患者注射了剂量，计划在未来三年内完成患者招募[9] Ginkgo Bioworks - Ginkgo Bioworks是一家具有潜在改变行业格局的细胞工程和生物安全公司，其生物制药收入去年同比增长40%[11] - Ginkgo已经与包括辉瑞和礼来在内的多家知名公司合作，其生物制药项目数量从2020年的7个增长到了现在的23个[12]

Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosec ...

公司活动 - Ginkgo Bioworks将于2024年4月11日在波士顿举办年度会议Ferment[1] - 会议将汇集来自合成生物学生态系统和Ginkgo社区的利益相关者，包括股东、客户、供应商、学者等[1] - 由于现场容量已满，公司将提供视频直播，包括在Ginkgo的YouTube频道和公司投资者关系网站上[2] 公司业务 - Ginkgo Bioworks是领先的细胞编程横向平台，提供灵活的端到端服务，解决各种市场的挑战，从食品和农业到制药、工业和特种化学品[3] - Ginkgo的生物安全和公共卫生部门Concentric by Ginkgo正在建立全球基础设施，以赋予政府、社区和公共卫生领导者预防、检测和应对各种生物威胁的能力[3] 公司信息获取 - 公司提供更多信息，请访问ginkgobioworks.com和concentricbyginkgo.com，阅读博客，或关注社交媒体渠道如X (@Ginkgo和@ConcentricByGBW)、Instagram (@GinkgoBioworks)、Threads (@GinkgoBioworks)或LinkedIn[3]